Stockscreener 앱 받기
3.50
1.69%
-0.06
Abpro Holdings Inc 주식(ABP)의 최신 뉴스
Published on: 2026-01-17 11:18:14 - baoquankhu1.vn
Technical Analysis: Whats Blackrock 2037 Municipal Target Term Trusts historical returnJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
US Market Recap: Is Intercont Cayman Limited in a bullish channelWeekly Profit Summary & Daily Momentum Trading Reports - baoquankhu1.vn
Momentum Shift: Is Abpro Holdings Inc stock technically oversold2025 Biggest Moves & Growth-Oriented Investment Plans - baoquankhu1.vn
New HER2 T-cell drug ABP-102 moves toward global trial after FDA nod - Stock Titan
Abpro Holdings Inc. (NASDAQ:ABP) Sees Significant Decrease in Short Interest - Defense World
Risk Off: What is the dividend yield of Nomad Foods Limited2025 Historical Comparison & Stock Timing and Entry Methods - baoquankhu1.vn
VIX Spike: What dividend safety score for Abpro Holdings Inc stockShare Buyback & Capital Efficient Trade Techniques - Bộ Nội Vụ
Abpro secures NASDAQ extension to regain compliance with listing rules - MSN
How Abpro Holdings Inc. stock compares to industry benchmarksLayoff News & Daily Profit Focused Screening - Улправда
Maxim Group Initiates Coverage of Abpro Holdings (ABP) with Buy Recommendation - MSN
Abpro Holdings, IncCommon Stock (NQ: ABP - FinancialContent
Why Abpro Holdings Inc. stock is a value investor pickWeekly Trade Summary & High Accuracy Investment Entry Signals - Улправда
Market Rankings: Can Abpro Holdings Inc Equity Warrant stock outperform in 2025 bull marketShare Buyback & Weekly High Return Stock Forecasts - moha.gov.vn
How institutional buying supports Abpro Holdings Inc. Equity Warrant stock2025 Major Catalysts & Accurate Trade Setup Notifications - ulpravda.ru
Can Abpro Holdings Inc. Equity Warrant stock outperform in 2025 bull marketWeekly Trade Report & Safe Capital Growth Tips - Улправда
Is Orchestra BioMed Holdings Inc. stock a dividend growth opportunityJuly 2025 Update & Daily Chart Pattern Signal Reports - ulpravda.ru
What momentum indicators show for Abpro Holdings Inc. stockJuly 2025 PreEarnings & Growth Oriented Trade Recommendations - Улправда
FDA clears Abpro and Celltrion’s solid tumor therapy for clinical trial - Investing.com Nigeria
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
FDA clears Abpro’s lead HER2 cancer drug for phase 1 - MSN
Abpro stock rises after FDA clearance for solid tumor program By Investing.com - Investing.com South Africa
Abpro stock rises after FDA clearance for solid tumor program - Investing.com
FDA clears Abpro and Celltrion’s solid tumor therapy for clinical trial By Investing.com - Investing.com South Africa
FDA Clears Abpro’s Lead HER2 Cancer Drug for Phase 1 - TipRanks
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72 - The Manila Times
Experimental HER2 cancer drug clears first FDA hurdle for human testing - Stock Titan
Published on: 2025-12-30 01:00:17 - moha.gov.vn
Aug Levels: Why Abpro Holdings Inc stock could rally in 2025July 2025 Price Swings & AI Forecasted Entry/Exit Points - moha.gov.vn
Abpro Holdings Inc. (NASDAQ:ABP) Short Interest Update - Defense World
Aug Selloffs: How Abpro Holdings Inc. Equity Warrant stock reacts to job market dataTrade Volume Report & Fast Gain Stock Tips - Улправда
How Abpro Holdings Inc. Equity Warrant stock valuations compare to rivalsQuarterly Profit Report & Expert Curated Trade Ideas - Улправда
Is Abpro Holdings Inc. Equity Warrant stock a smart buy before Fed meetingTrade Risk Assessment & Weekly Momentum Picks - Улправда
How Abpro Holdings Inc. Equity Warrant stock benefits from tech adoptionQuarterly Trade Report & Free Weekly Watchlist of Top Performers - Улправда
Net current asset value per share of Abpro Holdings, Inc. Warrant 2024-12.11.29 on Abpro Hldgs – NASDAQ:ABPWW - TradingView — Track All Markets
How Abpro Holdings Inc. Equity Warrant stock reacts to job market dataJuly 2025 Trade Ideas & AI Driven Price Predictions - Улправда
Can Abpro Holdings Inc. Equity Warrant stock rebound after recent weaknessQuarterly Trade Summary & Free Growth Oriented Trading Recommendations - Улправда
What Wall Street predicts for Abpro Holdings Inc. stock priceTrade Performance Summary & Daily Growth Stock Investment Tips - DonanımHaber
Why Abpro Holdings Inc. Equity Warrant stock remains undervalued - Улправда
How interest rate cuts could boost Abpro Holdings Inc. stockWeekly Profit Report & Safe Capital Growth Plans - DonanımHaber
Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy? - Defense World
Chipmakers Recap: How Abpro Holdings Inc. stock compares to industry benchmarks2025 Volatility Report & Target Return Focused Stock Picks - Улправда
Abpro Hldgs (ABP) Stock Analysis Report | Financials & Insights - Benzinga
Aug Patterns: How Abpro Holdings Inc. Equity Warrant stock valuations compare to rivals2025 Market Sentiment & AI Forecasted Stock Moves - ulpravda.ru
Abpro and Celltrion announce IND filing for T-cell engager - BioWorld MedTech
Abpro Holdings submits IND application for Phase 1 trial of ABP102/CT-P72 - TipRanks
Abpro Holdings Submits IND Application for Cancer Drug - TipRanks
Abpro Holdings, Inc. Submits IND for Phase 1 Trial of ABP-102/CT-P72 - TradingView — Track All Markets
Abpro Holdings (NASDAQ: ABP) discloses IND filing for HER2 therapy - Stock Titan
Abpro Holdings announces submission of an IND application to initiate a Phase 1 clinical trial of T cell engager ABP-102/CT-P72 for HER2-positive cancers - marketscreener.com
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Abpro Holdings Announces Submission of an IND Application - GlobeNewswire
Abpro Holdings Granted Nasdaq Compliance Extension - TipRanks
Abpro Holdings granted Nasdaq compliance extension - MSN
Abpro Holdings, Inc. Granted Nasdaq Listing Extension - TradingView — Track All Markets
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives - marketscreener.com
4.73%
0.92%
자본화:
|
볼륨(24시간):